5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Astrazeneca Pharma India Ltd.

•
astrazenecaindia.com/indiaBSE: 506820NSE: ASTRAZEN
Market Cap₹ 17,162 Cr.
Current Price
High / Low₹ 9,850 / 6,830
Stock P/E101.2
Book Value₹ 362
Price to Book22.39
Dividend Yield0.52 %
ROCE31.2 %
ROE23.0 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Injectables: 46.6% • Tablets: 46.0% • Clinical Trial Services: 5.1%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 28.8%
  • Company has a good return on equity (ROE) track record: 3 Years ROE 21.2%
  • Company has delivered good sales growth of 22.8% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 48.0%

CONS

  • Operating cash flow has been negative in recent years
  • Recent results are weak - TTM profit is down 15.5% versus prior year
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.17x)
  • Stock is trading at 22.4x its book value
  • Operating margins have contracted to 11.5% from 19.0%
  • Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1881.1037.31451338.900.852901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9570.5586.86254068.030.31902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4962.7586.55188767.060.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1150.0025.42114712.940.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1383.9533.17111803.570.94785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1945.5096.14105117.740.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1686.0026.1397008.710.241032.0325.229150.3517.4412.7620.54
8.LUPIN2112.0017.4796574.550.851416.9816.018276.8934.2828.8629.59
9.DRREDDY1151.5029.8396113.390.69435.60-69.108099.80-5.2113.7510.63
10.MANKIND2305.8546.6395242.000.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2477.3538.8969916.930.10482.83927.884018.4831.3520.3520.03
12.ASTRAZEN6864.80101.1817162.000.5237.93-32.06682.7929.7331.247.17
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
295311306383388408440480526559612579683
228258291334349355363394445484567518641
Operating Profit67531549385377868175456142
OPM %22.76%16.96%4.92%12.89%9.82%12.88%17.49%17.98%15.41%13.45%7.33%10.53%6.12%
825109-498-2610111759
Interest001-0000111122
Depreciation444449918173465
Profit before Tax71732054-155142787573475851
Tax %24.57%28.63%22.55%27.37%22.23%24.69%26.58%25.77%25.26%25.54%29.97%22.81%25.26%
Net Profit54521639-123831585654334538
21.5420.966.3215.79-4.7215.3712.3423.3022.3321.6913.0417.9515.17

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
5445717288328148061,0031,2961,7162,2762,432
5075256577116787198381,1111,4622,0142,209
Operating Profit37467112113586165184254262223
OPM %6.79%8.11%9.79%14.51%16.65%10.70%16.46%14.24%14.80%11.51%9.16%
141216131315-1451-562322
Interest00011111146
Depreciation1615151920171615402917
Profit before Tax36447311412783134220156252228
Tax %43.52%40.84%25.07%36.64%26.59%25.82%25.96%26.43%25.98%25.65%25.69%
Net Profit20265472936299162116188170
EPS8.0010.4021.8028.9037.3024.6039.7064.6046.3075.01—
Dividend Payout %0.00%0.00%0.00%3.46%5.36%40.58%40.29%37.15%69.12%47.99%—

COMPOUNDED SALES GROWTH

10 Years:
15%
5 Years:
23%
3 Years:
31%

COMPOUNDED PROFIT GROWTH

10 Years:
43%
5 Years:
15%
3 Years:
24%

STOCK PRICE CAGR

10 Years:
21%
5 Years:
17%
3 Years:
16%
1 Year:
-24%

RETURN ON EQUITY

10 Years:
18%
5 Years:
19%
3 Years:
21%
Last Year:
23%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Jul 31

₹ 18

Rs.36.0000 per share(1800%)Final Dividend

2025

Jul 18

₹ 16

Rs.32.0000 per share(1600%)Dividend

2024

Jul 5

₹ 12

Rs.24.0000 per share(1200%)Dividend

2023

Jul 14

₹ 8

Rs.16.0000 per share(800%)Dividend

2022

Jul 7

₹ 4

Rs.8.0000 per share(400%)Final Dividend

2021

Aug 18

₹ 1

Rs.2.0000 per share(100%)Interim Dividend

2020

Aug 20

₹ 1

Rs.2.0000 per share(100%)Interim Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital5555555555
216240294358450504581704758861
0009954338119
Trade Payables88127168210178190228197456783
205203124194233272324369580609
Total Liabilities5145755917768749771,1421,2771,8382,377
877575728174696764117
Capital Work in Progress54724421000
581131181651601401902285481,027
0000000153185214
Cash & Bank116126173253352448500506537449
249257218262277312381323503570
Total Assets5145755917768749771,1421,2771,8382,377

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
501390121137126992865-15
Cash from Investing0-94-171173518223119
Cash from Financing000-6-9-9-24-44-66-92
38-159-902699652531-88

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
75.0075.0075.0075.0075.0075.0075.0075.0075.00
2.792.902.922.893.032.742.712.782.68
4.995.085.204.644.545.255.545.786.07
Government0.000.000.000.000.000.000.000.000.00
17.2117.0116.8717.4817.4217.0116.7416.4416.25

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-02
General Updates

2026-09-02 - AstraZeneca Pharma India Limited has informed the Exchange about General Updates

2026-08-25
Action(s) taken or orders passed

2026-08-25 - AstraZeneca Pharma India Limited has informed the Exchange about Action(s) taken or orders passed

2026-08-24
General Updates

2026-08-24 - AstraZeneca Pharma India Limited has informed the Exchange about General Updates

2026-08-21
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-21 - AstraZeneca Pharma India Limited has informed the Exchange about Schedule of meet

2026-08-15
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-15 - AstraZeneca Pharma India Limited has informed the Exchange about Schedule of meet

2026-08-12
Shareholders meeting

2026-08-12 - AstraZeneca Pharma India Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 10, 2026. Further, the company has informed the Exchange regarding voting results.

2026-08-11
Press Release

2026-08-11 - AstraZeneca Pharma India Limited has informed the Exchange regarding a press release dated August 10, 2026, titled "Press Release".

2026-08-10
Shareholders meeting

2026-08-10 - AstraZeneca Pharma India Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 10, 2026

2026-08-10
Outcome of Board Meeting

2026-08-10 - AstraZeneca Pharma India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

News

Recent coverage and analyst commentary for ASTRAZEN

Loading news…

🤖

AI Stock Analyst

Astrazeneca Pharma India Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login